NWBO logo

Northwest Biotherapeutics, Inc. Stock Price

OTCPK:NWBO Community·US$321.6m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

NWBO Share Price Performance

US$0.18
-0.05 (-22.88%)
US$0.18
-0.05 (-22.88%)
Price US$0.18

NWBO Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Low risk with limited growth.

3 Risks
2 Rewards

Northwest Biotherapeutics, Inc. Key Details

US$1.5m

Revenue

US$25.3m

Cost of Revenue

-US$23.8m

Gross Profit

US$21.5m

Other Expenses

-US$45.3m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.027
-1,589.51%
-3,023.98%
-156.1%
View Full Analysis

About NWBO

Founded
1996
Employees
105
CEO
Linda Powers
WebsiteView website
www.nwbio.com

Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

Recent NWBO News & Updates

Recent updates

No updates